"Building on Indiana's Strength in Diabetes Research, Diagnostics, and Therapeutics"

Tuesday, November 13, 2007
07:30 a.m. - 05:15 p.m.
Location:
Eli Lilly Corporate Center, Building 93 Auditorium,
Indianapolis, IN

Join us for the first-ever effort to bring together a broad range of Indiana institutions and individuals with a common interest in diabetes focused R&D. This event will coincide with the 2007 World Diabetes Day and provide a unique combination of presentations, roundtable discussions and networking.
Summit Goals: Facilitate opportunities for inter-institution networking and collaboration Articulate key needs of Indiana-based pharma, biotech, and academia with respect to new R&D technologies and capabilities Celebrate and highlight Indiana-based R&D achievements and new technologies Foster further development of industry-academic efforts directed towards diabetes R&D
Agenda
7:30am-8:00am	Registration
8:00am-8:10am	Welcome David Moller, MD, Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Company Dan Peterson, Vice President, Industry & Government Affairs, Cook Group Inc., Chairman, IHIF
8:10am-9:15am	Keynote Presentation Bernard Zinman, MD, Mt. Sinai Hospital, University of Toronto, Clinical unmet needs, clinical pathogenesis and epidemiology
9:15am-10:15am	Plenary Session I – Therapeutics Thomas (Gus) Gustafson, PhD, Chief Scientific Officer, Diabetes Discovery Research, Eli Lilly and Company, Pharma Discovery Research Initiatives – in Search of New Therapeutic Approaches to Type 2 Diabetes Alexei Kharitonenkov, PhD, Principal Research Scientist, Biotherapeutic Lead Generation, Eli Lilly and Company, New Protein Based Therapies for Diabetes
10:15am-10:30am	Breakout / Poster Review
10:30am-11:30am	Plenary Session I – Therapeutics (continued) Bob McCarthy, PhD, VitaCyte LLC, Current status and future challenges for isolating islets for cellular therapy Matthias Tschoep, MD, University of Cincinnati, Molecular control of energy, glucose and lipid metabolism in health and disease
11:30am-12:30pm	Lunch and Poster Session
12:30pm-2:00pm	Plenary Session II – Devices and Diagnostics Moderated by: Martin Gerber, PhD, Roche Diagnostics Speakers: Jarema Kochan, PhD, Roche Pharmaceuticals, Nutley, New Jersey, Biomarkers in Diabetes – What will they bring to Therapy and Diagnostics? Matthias Axel Schweitzer, MD, Roche Diagnostics, Diabetes Care, Mannheim, Germany The Neuroendocrine Control of Metabolism as a Drug Target for Obesity James Collins, PE, MBA, Executive Director, Drug Delivery and Device R&D, Eli Lilly and Company, Novel drug delivery systems for diabetes
2:00pm-2:15pm	Break / Poster Review
2:15pm-4:30pm	Plenary Session III – Translational Research from Bench to Bedside Moderated by: Craig Brater, MD, Dean, Indiana University School of Medicine Speakers: Michael Sturek, PhD, Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Animal model approaches to facilitate translating basic concepts into clinical therapies for metabolic disease, diabetes David Marrero, PhD, J.O Ritchey Professor of Medicine, Indiana University School of Medicine, History of clinical diabetes research with an emphasis on new pharmacologic agents and medical devices. Clinical research infrastructure at IUSM with emphasis on RMRS, ResNet William Polonsky, PhD, Assistant Clinical Professor in Psychiatry, University of California, San Diego, The Psychological Side of Diabetes: How current and future technological innovations could transform patients’ attitudes and promote more effective self management Wesley Wong, MD, MMM, Associate Medical Director, Anthem Blue Cross and Blue Shield, The Role of a Health Benefits Company from Disease Management to Medical Policy
4:30pm-5:15pm	Roundtable: Where do we go from here? Moderated by: Richard DiMarchi, PhD, Professor of Chemistry, Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University Matthias Axel Schweitzer, MD, Roche Diagnostics, Diabetes Care, Mannheim, Germany Craig Brater, MD, Dean, Indiana University School of Medicine Thomas Bumol, PhD, Vice President, Biotechnology Discovery Research/Applied Molecular Evolution, Lilly Research Laboratories, Eli Lilly and Company David Moller, MD, Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Company Paris Roach, MD, Associate Professor of Clinical Medicine, Indiana University School of Medicine
5:15pm	Adjourn Dan Peterson, Vice President, Industry & Government Affairs, Cook Group Inc., Chairman, IHIF